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Abstract
The contribution of epithelial–mesenchymal transition (EMT) to human lung fibrogenesis is controversial. Here we provide
evidence that ZEB1-mediated EMT in human alveolar epithelial type II (ATII) cells contributes to the development of lung
fibrosis by paracrine signalling to underlying fibroblasts. Activation of EGFR–RAS–ERK signalling in ATII cells induced EMT
via ZEB1. ATII cells had extremely low extracellular matrix gene expression even after induction of EMT, however conditioned
media from ATII cells undergoing RAS-induced EMT augmented TGFβ-induced profibrogenic responses in lung fibroblasts.
This epithelial–mesenchymal crosstalk was controlled by ZEB1 via the expression of tissue plasminogen activator (tPA). In
human fibrotic lung tissue, nuclear ZEB1 expression was detected in alveolar epithelium adjacent to sites of extracellular matrix
(ECM) deposition, suggesting that ZEB1-mediated paracrine signalling has the potential to contribute to early fibrotic changes in
the lung interstitium. Targeting this novel ZEB1 regulatory axis may be a viable strategy for the treatment of pulmonary fibrosis.
Introduction
Epithelial–mesenchymal transition (EMT), a dynamic and
reversible biological process by which epithelial cells lose
their cell polarity and down-regulate cadherin-mediated
cell–cell adhesion to gain migratory properties, is involved in
embryonic development, wound healing, fibrosis and cancer
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metastasis [1]. EMT is executed in response to pleiotropic
signalling factors, including the transforming growth
factor β (TGFβ) superfamily, Sonic Hedgehog (Shh),
Wnt/β-catenin, fibroblast growth factor (FGF) and epi-
dermal growth factor (EGF). These factors regulate the
expression of specific transcription factors (TFs) called
EMT-TFs (e.g. Snail, ZEB, Twist and others) that pro-
mote repression of epithelial features and induction of
mesenchymal characteristics [2, 3]. Unlike EMT in can-
cer, which is detrimental, wound-healing-driven EMT
induced in response to injury is beneficial, but exag-
gerated healing responses can lead to fibrosis or tissue
scarring.
Fibrosis is a hallmark of many chronic degenerative dis-
orders and is associated with reduced organ function and
eventual organ failure. Fibrotic disease is on the increase; for
example, idiopathic pulmonary fibrosis (IPF), the most com-
mon type of idiopathic interstitial pneumonia, occurs with
similar frequency to that of stomach, brain and testicular
cancer [4]. IPF is now generally regarded as a consequence of
multiple interacting genetic and environmental risk factors,
with repetitive local micro-injuries to ageing alveolar epithe-
lium playing a central role [5]. These micro-injuries initiate
the progressive accumulation of extracellular matrix (ECM)
deposited by myofibroblasts. The origin of these myofibro-
blasts has been debated for many years, with EMT being
considered as a potential source by driving the transformation
of epithelial cells into ECM producing myofibroblasts [6–10].
However, lineage tracing in transgenic mice indicates that the
contribution of those cells to the population of myofibroblasts
is negligible [11–14].
In this study, we identify a novel regulatory axis
involved in lung fibrosis whereby EMT contributes to the
fibrotic process via paracrine activation of fibroblasts. We
demonstrate that epidermal growth factor receptor (EGFR)-
RAS-extracellular signal-regulated kinase (ERK) signalling
induces the transcription factor ZEB1, which not only
controls EMT but also regulates the production of locally-
acting mediators. Specifically, we identified tissue plasmi-
nogen activator (tPA) as a downstream effector of ZEB1
transcriptional activity that contributes to paracrine signal-
ling by enhancing TGFβ-induced profibrogenic responses in
fibroblasts. Consistent with this, increased ZEB1 nuclear
expression was detected in alveolar epithelium adjacent to
sites of ECM deposition in IPF lung tissue. Thus, rather
than contributing directly to the mesenchymal population,
our data suggest that ZEB1-dependent EMT of ATII cells
contributes to fibrosis via epithelial–fibroblast crosstalk.
The occurrence of ZEB1 activation at sites of local ECM
deposition in IPF lung tissue is consistent with the concept
that ZEB1-regulated paracrine signalling contributes to the
development of a profibrogenic microenvironment leading
to interstitial lung fibrosis.
Results
Activation of EGFR signalling induces EMT in
alveolar epithelial cells
To investigate IPF associated signalling pathways, we analysed
differentially expressed genes in IPF and control lung tissue
from a publicly available microarray dataset (GSE24206) [15].
Using a false discovery rate (FDR) corrected P value of 0.05,
we identified 7668 genes to be differentially expressed out of a
total of 54,675 probe sets. Gene network analysis using the
Consensus Pathways Database [16] identified a number of
pathways. Of these the EGFR–ERK pathway was the top-
ranked pathway with 150 of 458 pathway candidates being
significantly (Q-value < 0.05) overrepresented in the dataset
(Supplementary Fig. S1a).
Based on the transcriptomic data, we hypothesised an
important role of EGFR signalling in IPF. Identification
of pathological mechanisms of IPF has been challenging;
however, dysregulation of alveolar type 2 (ATII) epithe-
lial cells is thought to be central [5]. We therefore treated
a human ATII cell line (ATIIER:KRASV12) [17, 18] with
EGF (Fig. 1b–d; Supplementary Fig. S1b) or transform-
ing growth factor α (TGFα) (Supplementary Fig. S1b) to
activate EGFR signalling. The human ATII cell line
grows in continuous culture and expresses the ATII cell
marker, pro-surfactant protein C (ProSP-C) (Figs. 1a, 2f).
Our results showed that treatment of ATIIER:KRASV12
cells with EGF for 24 h induced EMT, reflected by a
change in their morphology from typical cuboidal epi-
thelial cells to a more elongated mesenchymal cell phe-
notype with a reorganisation of the actin cytoskeleton as
demonstrated using Phalloidin staining of filamentous
actin (F-actin) (Fig. 1b). This phenotypic switch was
accompanied by a significant increase in mRNA expres-
sion of ZEB1 and VIM (Vimentin), and a reduction in
CDH1 (E-cadherin); mRNA levels of other EMT-TFs,
such as SNAI1, SNAI2, TWIST and ZEB2 were not
increased by activation of EGFR signalling (Fig. 1c). The
changes in ZEB1 and E-cadherin were further confirmed
by Western blot analysis (Fig. 1d; Supplementary
Fig. S1b).
Similar results were obtained using primary human ATII
cells treated with EGF where an increase in ZEB1 expres-
sion was associated with down-regulation of E-cadherin
(Fig. 1e). Under the same conditions, however, TGFβ was
not able to induce EMT in the primary human ATII cells
(Fig. 1e). Together, these results demonstrate that activation
of EGFR signalling is able to activate the EMT programme
in ATII cells, which is supported by a morphology change,
the induction of the EMT-TF ZEB1 and a mesenchymal
marker Vimentin as well as a reduction in E-cadherin
expression.
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Activation of the RAS pathway drives EMT via
ERK–ZEB1 in ATII cells
RAS signalling is one of the most important pathways
downstream of EGFR activation and is involved in a variety
of physiological and pathological responses, including EMT
[19–21]. To investigate whether the RAS pathway is impor-
tant for EMT in ATII cells, we utilised a RAS-inducible ATII
cell model. KRASV12 (containing a single amino acid
mutation in KRAS, glycine to valine at position 12) fused to
the oestrogen receptor (ER) ligand-binding domain [22] was
introduced into ATII cells to generate ATIIER:KRASV12,
in which KRASV12 expression is induced by 4-
hydroxytamoxifen (4-OHT) [17, 18]. Like EGF, direct
activation of the RAS pathway in ATIIER:KRASV12 cells by
treatment with 4-OHT induced EMT, reflected by a reduction
in E-cadherin levels and an increase in ZEB1 and Vimentin
expression (Fig. 2a, b). Time-course analysis further demon-
strated that the induction of ZEB1 by RAS activation pre-
ceded the down-regulation of E-cadherin (Fig. 2c).
Consistently, an EMT morphology change with an increase in
ZEB1 expression was observed upon RAS activation
(Fig. 2d). When grown on a thick layer of Matrigel, ATII cells
form spheres (a 3D culture model) [23]. We adopted this
experimental system and used ATIIER:KRASV12 cells to
investigate whether RAS activation induces EMT in 3D
cultures. Control ATIIER:KRASV12 cells formed single round
spheres. Induction of oncogenic KRAS by 4-OHT resulted in
spheres invading into the Matrigel with protrusions (Fig. 2e;
Supplementary Fig. S2). We recovered these cells from the
Matrigel, and examined the protein expression. We confirmed










Fig. 1 Activation of EGFR signalling induces EMT in alveolar epi-
thelial cells. a Immunofluorescence staining of Pro-surfactant protein-
C (Pro-SP-C) (green) in ATIIER:KRASV12 cells. DAPI (blue) was used to
stain nuclei. Scale bars: 40 μm. b Immunofluorescence staining of F-
actin (red) in ATIIER:KRASV12 cells cultured in the absence or presence
of 100 ng/ml EGF for 24 h. Rhodamine-phalloidin was used to stain F-
actin. DAPI (blue) was used to stain nuclei. Scale bars: 40 μm. c Fold
change in mRNA levels of CDH1 (E-cadherin), VIM (Vimentin),
SNAI1 (Snail1), SNAI2 (Snail2), TWIST, ZEB1 and ZEB2 in ATIIER:
KRASV12 cells cultured in the absence or presence of 100 ng/ml EGF for
24 h. GAPDH-normalised mRNA levels in control cells were used to
set the baseline value at unity. Data are mean ± s.d. n= 3 samples per
group. **P < 0.01. ***P < 0.001. d Protein expression of E-cadherin,
ZEB1 and phospho-ERK (p-ERK) in ATIIER:KRASV12 treated with
100 ng/ml EGF for 8 or 24 h. β-actin was used as a loading control.
e Protein expression of E-cadherin, ZEB1, phospho-Smad2
(p-Smad2), phospho-ERK (p-ERK) in primary human ATII cells
treated with 100 ng/ml EGF or 5 ng/ml TGFβ over 7 days. β-actin was
used as a loading control
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demonstrated by a reduction in E-cadherin, and an increase in
ZEB1 and Vimentin expression (Fig. 2f). These observations
suggest that EGFR signalling and the downstream RAS
pathway are able to induce EMT in ATII cells.
Since RAS activity regulates both the RAF–ERK and
phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT)
signalling pathways, we next investigated which one is
required for EMT in the ATII cells using inhibitors for these
pathways. Treatment with the ERK inhibitor U0126 in
ATIIER:KRASV12 cells was sufficient to inhibit RAS-induced
ZEB1 and Vimentin expression, as well as to restore the
expression of E-cadherin and the epithelial morphology; in
contrast, the AKT inhibitor AKT VIII failed to do so


















Fig. 2 Activation of RAS signalling induces EMT in alveolar epithelial
cells. a Protein expression of E-cadherin, ZEB1 and phospho-ERK (p-
ERK) in ATIIER:KRASV12 treated with 100 ng/ml EGF or 250 nM 4-OHT
for 24 h. β-tubulin was used as a loading control. b Fold change in
mRNA levels of CDH1 (E-cadherin), VIM (Vimentin), SNAI1 (Snail1),
SNAI2 (Snail2), TWIST, ZEB1 and ZEB2 in ATIIER:KRASV12 cells cul-
tured in the absence or presence of 250 nM 4-OHT for 24 h. GAPDH-
normalised mRNA levels in control cells were used to set the baseline
value at unity. Data are mean ± s.d. n= 3 samples per group. ***P <
0.001. c Protein expression of E-cadherin, ZEB1, ZEB2, phospho-ERK
(p-ERK) and phospho-AKT (p-AKT) in ATIIER:KRASV12 treated with
250 nM 4-OHT for the indicated period. β-actin was used as a loading
control. d Immunofluorescence staining of ZEB1 (green) and F-actin
(red) in ATIIER:KRASV12 cells cultured in the absence or presence of
250 nM 4-OHT for 24 h. Rhodamine-phalloidin was used to stain
F-actin. DAPI (blue) was used to stain nuclei. Scale bars: 40 μm.
e Representative 3D confocal images of ATIIER:KRASV12 cells cultured in
Matrigel in the absence or presence of 250 nM 4-OHT for 48 h. Spheres
were stained for F-actin with Rhodamine-phalloidin (red) and DAPI
(blue). Scale bars: 40 μm. f Western blot analysis of lysates from 3D-
cultured ATIIER:KRASV12 cells in Matrigel treated without or with 250 nM
4-OHT for 48 h showing effects on E-cadherin, ZEB1, Vimentin,
phospho-ERK (p-ERK), phospho-AKT (p-AKT) and Pro-surfactant
protein-C (Pro-SP-C). β-actin was used as a loading control
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We next investigated which EMT-TFs are important for
RAS-induced EMT in ATII cells. ZEB1 RNA interference
(RNAi), but not SNAI1 or SNAI2 RNAi, was able to restore
E-cadherin expression and the epithelial morphology in 4-
OHT-treated ATIIER:KRASV12 cells (Fig. 3c, d; Supplemen-
tary Fig. S3b), in line with the fact the ZEB1 was the only
EMT-TF induced by EGFR–RAS signalling (Figs. 1, 2).
Taken together, our results identify that RAS activation in
human ATII cells drives EMT via ERK–ZEB1 pathway.
ZEB1 is highly expressed in IPF alveolar epithelium
and is critical for transcriptional regulation of
secreted factors that mediate crosstalk between ATII
cells and fibroblasts
Given our in vitro findings, we compared ZEB1 expression
in IPF and control lung tissue. In IPF tissue, we detected
strong nuclear expression of ZEB1 not only in fibroblastic
foci (Fig. 4a) but also in epithelial cells of thickened alveoli
septae where collagen deposition in the interstitium was
evident (Fig. 4b); in contrast, little ZEB1 staining or col-
lagen deposition was observed in alveoli of control lung
tissue (Fig. 4c). The presence of nuclear ZEB1 staining in
alveolar epithelial cells within IPF lung tissue suggests that
these cells are undergoing EMT; furthermore, the presence
of ECM suggests induction of mesenchymal responses,
either directly via the repairing epithelial cells undergoing
EMT or by crosstalk with underlying fibroblasts.
Comparison of the relative expression of ECM compo-
nents in RAS-activated ATIIER:KRASV12 cells and fibroblasts
highlights that ATII cells produce extremely low levels of
ECM genes even after the induction of EMT (Supplemen-
tary Fig. S4a), suggesting that ECM production in fibrosis is
more likely to be a consequence of fibroblast activation than
direct deposition by epithelial cells undergoing EMT.
Therefore we investigated whether ATII cells undergoing
RAS-induced EMT produce paracrine factors that activate











Fig. 3 Activation of the RAS pathway drives EMT via ERK–ZEB1 in
ATII cells. a Protein expression of E-cadherin, ZEB1, phospho-AKT
(p-AKT) and phospho-ERK (p-ERK) in ATIIER:KRASV12 treated with
250 nM 4-OHT in the absence or presence of inhibitors AKT VIII
(10 μM) or U0126 (10 μM) for 24 h. DMSO was used as a vehicle
control and β-actin was used as a loading control. b Fold change in
mRNA levels of CDH1 (E-cadherin), VIM (Vimentin) and ZEB1 in
ATIIER:KRASV12 treated with 250 nM 4-OHT in the absence or presence
of inhibitors AKT VIII (10 μM) or U0126 (10 μM) for 24 h. DMSO
was used as a vehicle control. GAPDH-normalised mRNA levels in
control cells were used to set the baseline value at unity. Data are
mean ± s.d. n= 3 samples per group. **P < 0.01. ***P < 0.001.
c Protein expression of E-cadherin, ZEB1, Snail1 and Snail2 in
ATIIER:KRASV12 cells transfected with the indicated siRNA followed by
treatment of 250 nM 4-OHT for 24 h. β-tubulin was used as a loading
control. d Fold change in the mRNA level of CDH1 (E-cadherin) in
ATIIER:KRASV12 cells transfected with the indicated siRNA followed by
treatment of 250 nM 4-OHT for 24 h. GAPDH-normalised mRNA
levels in control cells were used to set the baseline value at unity. Data
are mean ± s.d. n= 3 samples per group. ***P < 0.001
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ability of 4-OHT to induce RAS pathway activation in
ATIIER:KRASV12 cells, as this was not dependent on exo-
genous growth factors that might directly affect fibroblast
responses. We treated the MRC5 or primary human par-
enchymal lung fibroblasts with conditioned media (CM)
from control or 4-OHT-treated ATIIER:KRASV12 cells in the
absence or presence of TGFβ, and evaluated the fibroblast
responses by measuring the expression of α-smooth muscle
actin (α-SMA, a myofibroblast marker) and other ECM
genes, including COL1A1, COL3A1 and FN1. On its own,
CM from RAS-activated ATIIER:KRASV12 cells (4-OHT-
treated ATII CM) had little effect on the activation of
fibroblasts (Fig. 5). However, 4-OHT-treated ATII CM
together with TGFβ achieved a synergistic effect in
activating fibroblasts, reflected by a larger increase in α-
SMA (ACTA2), COL1A1 and FN1 levels (Fig. 5a, b). Of
note, 4-OHT-treated ATII CM did not augment Smad2
phosphorylation suggesting a Smad2-independent response
(Fig. 5a, c). Similar results were obtained using primary
human lung fibroblasts from IPF patients (IPF fibroblasts,
IPFFs) and control donors (normal human lung fibroblasts,
NHLFs) (Fig. 5c; Supplementary Fig. S4b).
Given the important role of ZEB1 in mediating RAS-
induced EMT and the fact that ZEB1 is highly expressed in
the alveolar epithelium of IPF patients, we hypothesised
that ZEB1 may determine the paracrine signalling produced
by ATII cells undergoing RAS-induced EMT. ZEB1 RNAi






































TrichromeFig. 4 ZEB1 is highly expressed
in IPF fibroblastic foci and
epithelial cells of thickened
alveoli septae where collagen
deposition in the interstitium is
also evident. Serial sections of
IPF (fibroblastic foci in a and
epithelial cells of thickened
alveoli septae in b) or control
lung tissue (c) were stained for
ZEB1 (left panel), with H/E
(middle panel) or Masson’s
trichrome stain (right panel,
collagen shown in blue). n= 3.
Arrows: representative positive
ZEB1 staining. **—a
fibroblastic focus. Scale bars:
50 μm
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CM from RAS-activated ATII cells on TGFβ-induced
activation of fibroblasts (Fig. 6b; Supplementary Fig. S5),
highlighting ZEB1 as a key regulator of EMT as well as the
paracrine signalling between ATII cells and fibroblasts.
ZEB1 regulates the expression of tissue
plasminogen activator, which acts as a paracrine
regulator of TGFβ-induced fibroblast activation
By performing quantitative proteomic analysis of the CM
from control or 4-OHT-treated ATIIER:KRASV12 cells, we
identified ~430 secreted proteins whose levels changed
during RAS-induced EMT. We then checked their expres-
sion in pulmonary epithelial cells from control and IPF lung
tissue using a publicly available dataset [24], and identified
a total number of 25 genes/proteins that were elevated in
IPF lung epithelial cells as well as in CM from 4-OHT-
treated ATIIER:KRASV12 cells (Supplementary Table S1). Of
these, PLAT, which encodes tPA was most up-regulated in







Fig. 5 ATII cells undergoing RAS-induced EMT induce fibroblast
activation via paracrine signalling. a Protein expression of α-SMA and
phospho-Smad2 (p-Smad2) in MRC5 lung fibroblasts treated without
or with 5 ng/ml TGFβ in the presence of conditioned media (CM) from
control or 4-OHT-treated ATIIER:KRASV12 cells for 48 h. β-actin was
used as a loading control. b Fold change in mRNA levels of COL1A1,
COL3A1, FN1 and ACTA2 in MRC5 lung fibroblasts with indicated
treatments. β-actin-normalised mRNA levels in control cells were used
to set the baseline value at unity. Data are mean ± s.d. n= 3 samples
per group. *P < 0.05. ***P < 0.001. c Protein expression of α-SMA
and phospho-Smad2 (p-Smad2), and fold change in the mRNA level
of ACTA2 (α-SMA) in primary human lung fibroblasts from IPF
(IPFFs) or from normal healthy lung (NHLFs) with indicated treat-
ments. β-tubulin was used as a loading control in Western blots. β-
actin-normalised mRNA levels in control cells were used to set the
baseline value at unity (indicated above bars). Data are mean ± s.d.









Fig. 6 ZEB1 is a key regulator of the paracrine signalling between ATII
cells and fibroblasts. a Protein expression of ZEB1, E-cadherin,
phospho-ERK (p-ERK) and phospho-AKT (p-AKT) in ATIIER:KRASV12
cells with indicated treatments. β-tubulin was used as a loading control.
b Protein expression of α-SMA and phospho-Smad2 (p-Smad2) in
MRC5 lung fibroblasts or primary human lung fibroblasts from IPF
(IPFFs) with indicated treatments. β-tubulin was used as a loading
control
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we confirmed enhanced secretion of tPA in the CM from 4-
OHT-treated ATIIER:KRASV12 cells by Western blotting
(Fig. 7b). As we had identified ZEB1 as the key regulator of
epithelial–mesenchymal crosstalk, we scanned the promoter
of PLAT for the presence of ZEB1 binding motifs (5′-
CANNTG-3′) and found a ZEB1 binding site −419 bp
upstream of the transcriptional start site (TSS) (Supple-
mentary Fig. S6a). Further experiments showed that the
mRNA expression of PLAT was increased upon RAS-
activation in ATII cells and this was repressed by ZEB1
RNAi (Fig. 7c).
To validate the ZEB1 binding site in the PLAT promoter,
we first performed a chromatin immunoprecipitation (ChIP)
assay. An anti-ZEB1 antibody was used to precipitate for-
maldehyde cross-linked ZEB1-DNA complexes in ATIIER:
KRASV12 cells treated without or with 4-OHT. The presence
of PLAT promoter DNA sequences in the immunoprecipi-
tate was verified by PCR using primers amplifying the
region between −547 and −345 upstream of the TSS, and
we found RAS activation in ATII cells increased ZEB1
occupancy on the PLAT promoter (Fig. 7d; Supplementary
Fig. S6b). We next generated two PLAT promoter con-
structs (−689 to −1 upstream of the TSS) which were
cloned into a pGL3 basic luciferase reporter plasmid and
transfected into ATII cells; the pGL3 basic-PLAT (−689 to
−1) construct contained the ZEB1 motif whereas this was
deleted in the second construct (delta −419 to −414
upstream of the TSS) (pGL3 basic-Δ ZEB1 motif). RAS
activation by 4-OHT in ATIIER:KRASV12 cells resulted in a
significant increase in pGL3 basic-PLAT (−689 to −1)
luciferase activity. Under the same conditions, luciferase
activity was not increased using pGL3 basic-Δ ZEB1 motif
(Fig. 7e). These data confirm that PLAT (tPA) is a tran-
scriptional target of ZEB1 in response to RAS activation in
ATII cells.
Consistent with a previous report [25], tPA synergisti-
cally promoted TGFβ-induced α-SMA expression in human
lung fibroblasts (Supplementary Fig. S6c). Like ZEB1,
PLAT RNAi (Supplementary Fig. S6d) in ATII cells com-
pletely abolished the effects of CM from RAS-activated
ATII cells on TGFβ-induced α-SMA expression in fibro-
blasts (Fig. 7f), demonstrating tPA as a key paracrine factor
secreted by ATII cells undergoing RAS-induced EMT.
These results provide clear evidence that a ZEB1-tPA axis
is involved in the paracrine signalling between ATII cells
undergoing RAS-induced EMT and fibroblasts to augment
their differentiation into myofibroblasts caused by TGFβ.
Finally, in view of the requirement for exogenous TGFβ
to demonstrate an effect of the 4-OHT-treated ATII CM on
fibroblasts, we investigated whether ATII cells in fibrotic
tissue in vivo or those undergoing injury/repair in vitro
expressed endogenous TGFβ. Using a publicly available
dataset [24], we found that the major TGFB isoform
expressed by alveolar epithelial cells in vivo was TGFB2
and that this was expressed at significantly higher levels in
IPF compared with control lung tissue (Supplementary
Fig. S7a). In contrast with the study in kidney [14], the data
also revealed that Snail2 is up-regulated in IPF vs. control
lung epithelial cells, but not Snail1 or Twist (Supplementary
Fig. S7b). As we have previously shown that scrape-
wounding of bronchial epithelial cells stimulates release of
TGFβ2 independently of EGFR activation [26], we exam-
ined whether damage of ATII cells similarly affected
TGFB2 expression. This showed that scrape-wounded ATII
cells expressed more TGFB2 and this increased in propor-
tion to the extent of injury (Supplementary Fig. S7c). These
data suggest that damaged ATII cells are a potential a
source of TGFβ in vivo.
Discussion
Fibrotic diseases are a major cause of morbidity and mor-
tality worldwide and their prevalence is increasing with an
ageing population. Abnormal wound healing responses
appear to make major contributions to the scarring process,
but the underlying pathological mechanisms are unclear,
especially the role of EMT. In this study, we have used a
variety of approaches to show that activation of
EGFR–RAS–ERK signalling in ATII cells induces EMT
via the transcriptional regulator ZEB1. Importantly, beyond
its effects on the epithelial cell phenotype, we have identi-
fied that ZEB1 is a regulator of paracrine signalling between
lung epithelial cells and fibroblasts, as ATII cells under-
going RAS-induced EMT secrete tPA to augment TGFβ-
induced myofibroblast differentiation (Fig. 8). This may be
an important profibrotic event as, relative to epithelial cells,
the ability of fibroblasts to synthesise ECM is orders of
magnitude greater.
Consistent with previous findings [27, 28], we found
strong expression of ZEB1 in the epithelium in proximity to
fibroblastic foci in IPF lung tissue. However, we also found
ZEB1 was expressed in epithelial cells of thickened alveolar
septae where ECM deposition was evident. This suggests
that ZEB1 is induced as an early response to alveolar epi-
thelial injury and that, by regulating the expression of fac-
tors involved in paracrine signalling, ZEB1 may promote
TGFβ-induced fibroblast activation in IPF. While this may
be a normal physiological response to injury, persistent
epithelial injury and/or failure to resolve the lesion may
sensitise the underlying fibroblasts to drive a pathologic
profibrogenic response. In line with this, exposure of human
lung cells to nickel (Ni), an environmental and occupational
pollutant linked to lung fibrosis [29], caused ZEB1-
dependent EMT, which was irreversible even after the ter-
mination of Ni exposure [30]. Thus, it is conceivable that
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repetitive environmental exposures to metals such as Ni
could lead to deregulation of ZEB1 to cause persistent EMT
and exaggerated profibrogenic crosstalk during the initiation
of IPF.
EMT in the ATII cells was strongly induced by EGFR
activation. The EGFR is a transmembrane receptor tyrosine
kinase activated by members of the EGF family, including





Fig. 7 ZEB1 regulates the expression of tissue plasminogen activator
(tPA), which acts as a paracrine regulator of TGFβ-induced fibroblast
activation. a Increased expression of PLAT (tPA) in IPF epithelial cells
is shown by an online LGEA web portal (https://research.cchmc.org/
pbge/lunggens/mainportal.html). b Quantitative secretome analysis
identifies an increased level of tPA in the conditioned media (CM) from
4-OHT-treated ATIIER:KRASV12 cells and a representative tPA Western
blot of CM from control or 4-OHT-treated ATIIER:KRASV12 cells. Data
are individual values with mean and s.d. n= 3 samples per group.
Values were normalised to total fmol of each sample multiplied by
10,000. c Fold change in mRNA levels of ZEB1 and PLAT (tPA) in
ATIIER:KRASV12 cells with indicated treatments. β-actin-normalised
mRNA levels in control cells were used to set the baseline value at
unity. Data are mean ± s.d. n= 3 samples per group. ***P < 0.001.
d ChIP assays of ZEB1's ability to bind the PLAT (tPA) promoter in
ATIIER:KRASV12 cells with indicated treatments. The amplified PLAT
(tPA) promoter region (−547 to −345) contains a ZEB1 binding site
at −419. Values represent relative binding in relation to input (2%),
normalised against control (1.0). Data are mean ± s.d. n= 4 samples
per group. ***P < 0.001. e PLAT promoter reporter assays in ATIIER:
KRASV12 cells with indicated treatments. Values represent relative fold
of firefly luciferase in relation to Renilla luciferase, normalised against
control (1.0). Data are mean ± s.d. n= 3 samples per group. **P < 0.01.
***P < 0.001. f Protein expression of α-SMA and phospho-Smad2 (p-
Smad2) in MRC5 lung fibroblasts with indicated treatments. β-tubulin
was used as a loading control
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more downstream effectors including the ERK, PI3K/AKT,
signal transducer and activator of transcription (STAT) and
mammalian target of rapamycin (mTOR) pathways through
receptor autophosphorylation and cytoplasmic protein
binding [32–34]. These in turn act as critical mediators of
airway and alveolar homoeostasis, with aberrant activation
within one or more pathway components capable of driving
a variety of respiratory pathologies, including lung fibrosis
[33, 35]. The EGFR pathway has been implicated in lung
fibrosis through studies in which transgenic mice that con-
stitutively express TGFα in epithelial cells develop pro-
gressive lung fibrosis [36, 37]. Conversely, mice deficient in
TGFα that lack normal EGFR signalling or that are treated
with EGFR pathway inhibitors exhibit resistance to
bleomycin-induced lung fibrosis [38]. In IPF patients,
EGFR mutations [39] or increased expression of the EGFR
[40] have been reported. Our evidence that an
EGFR–RAS–ERK–ZEB1 axis may contribute to the early
stages of lung fibrosis suggests that inhibiting EGFR sig-
nalling may be of clinical relevance for regulating human
fibrotic lung disease.
A key finding of our study was identification that ZEB1
controls tPA expression and that this affects the sensitivity
of fibroblast activation induced by TGFβ. While tPA is a
key activator of fibrinolysis, it also has direct cellular effects
by virtue of its ability to bind to the low-density lipoprotein
(LDL) receptor-related protein-1 (LRP-1), triggering LRP-1
tyrosine phosphorylation and recruitment of β1-integrin
signalling involving integrin-linked kinase (ILK) [25]. In
this context, tPA acts as a survival factor that protects
fibroblasts/myofibroblasts from apoptosis, and it has pre-
viously been implicated in kidney fibrosis [25], but no other
fibrotic conditions. In keeping with a role of tPA in human
lung fibrosis was the identification in a publicly available
dataset [24] that there is an increased expression of PLAT
(tPA) by IPF epithelial cells.
EMT converts epithelial cells into migratory and/or
invasive mesenchymal cells, and is well established during
development and carcinogenesis, however, its role in
fibrosis has been more controversial [1, 3, 41]. Although
human IPF tissue studies have demonstrated co-localisation
of epithelial and mesenchymal markers [27, 28, 42], the
number of fibroblasts arising from epithelial cells was small
in some mouse lineage tracing studies [11, 12], suggesting
effects of EMT beyond direct phenotypic conversion into
matrix-producing cells. Recent studies in renal fibrosis have
reported that tubular epithelial cells undergoing EMT relay
signals to the interstitium, which promote myofibroblast
differentiation and fibrogenesis, without directly contribut-
ing to the myofibroblast population [14, 43–45]. In tubu-
lointerstitial renal fibrosis, TGFβ induces EMT via Snail1,
and then Snail1 induces TGFβ expression generating an
autocrine loop that sustains the progression of the disease
by influencing the differentiation of fibroblasts into myofi-
broblasts [14]. In contrast with studies in kidney, our ana-
lysis of publicly available transcriptomic datasets of IPF
lung tissue, identified the EGFR–ERK pathway as the top-
ranked pathway with 150 of 458 pathway candidates being
significantly overrepresented in the IPF dataset, high-
lighting the potential importance of this pathway in IPF
pathogenesis. Building on these observations, our in vitro
studies of EGFR–RAS–ERK-induced EMT, identified
ZEB1 as the main transcription factor that controlled EMT
as well as paracrine signalling through regulation of tPA
expression, which potentiated fibroblast differentiation in
the presence of TGFβ. However, as these paracrine effects
required exogenous TGFβ, this raised the question of the
source of TGFβ in lung fibrosis in vivo. While many cell
types produce TGFβ isoforms which can also be stored as
latent growth factor bound in the ECM [46–48], we
focussed on the epithelium and found increased expression
of TGFB2, as well as SNAI2 in IPF epithelial cells using
publicly available datasets, with scrape wounding of ATII
cells also inducing TGFB2 expression in vitro. The
increased epithelial TGFB2 signature highlights the poten-
tial for EGF (ZEB1) and TGFβ (Snail2) to synergize in
paracrine activation of the underlying fibroblasts.
Together with previous findings in kidney fibrosis [14,
43], our study helps to provide a unified concept for the role
of EMT in fibrosis: persistent EMT of epithelial cells may
dysregulate paracrine signalling between epithelial and
Fig. 8 Diagram summarising a critical role of ZEB1-tPA axis regu-
lated by EGFR–RAS–ERK pathway in the development of lung
fibrosis (details provided in Discussion)
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mesenchymal cells, so creating a profibrogenic micro-
environment which leads to the development of fibrosis.
Based on the relative low levels of ECM biosynthesis by
epithelial cells and the relatively small numbers of
mesenchymal cells identified in lineage tracing studies [11,
12, 14, 43], this mechanism may be more important than
direct conversion of epithelial cells into mesenchymal cells.
While the finer details of these paracrine mechanisms may
vary according to disease and tissue location, our identifi-
cation of ZEB1 as a key regulator of EGF/RAS-induced
EMT and an enhancer of paracrine signalling mediating the
crosstalk between ATII cells and lung fibroblasts may help
to find drug targets or biomarkers to intervene or predict the
progression of pulmonary fibrosis.
Methods
Lung tissue sampling
All human lung experiments were approved by the South-
ampton and South West Hampshire and the Mid and South
Buckinghamshire Local Research Ethics Committees, and
all subjects gave written informed consent. Clinically indi-
cated IPF lung biopsy tissue samples and non-fibrotic con-
trol tissue samples (macroscopically normal lung
sampled remotely from a cancer site) were deemed surplus
to clinical diagnostic requirements. All IPF samples were
from patients subsequently receiving a multidisciplinary
diagnosis of IPF according to international consensus
guidelines [49].
Cell culture, reagents and transfections
Primary parenchymal lung fibroblast cultures were estab-
lished from IPF or control lung tissue as described pre-
viously [50]. Fibroblasts were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% foetal bovine serum (FBS), 50 units/ml penicillin, 50
μg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium
pyruvate and 1× non-essential amino acids (DMEM/FBS)
(all from Life Technologies).
Primary human ATII cells were isolated from macro-
scopically normal regions of surgically resected lung par-
enchyma as described previously [50, 51]. The alveolar
epithelial cells were resuspended in fresh DCCM-1 (Bio-
logical Industries Ltd.) supplemented with 10% new-born
calf serum (NBCS) (Life Technologies), 1% penicillin, 1%
streptomycin and 1% L-glutamine (all from Sigma Aldrich)
and plated on collagen 1 (PureCol 5005-b, Advanced Bio-
Matrix Inc.) coated 96 well plates at 60% density; purity of
the cultures was determined by staining for alkaline
phosphatase.
ATIIER:KRASV12 cells [17, 18] were cultured in DCCM-1
(Biological Industries Ltd.) supplemented with 10% NBCS
(Life Technologies), 1% penicillin, 1% streptomycin and 1%
L-glutamine (all from Sigma Aldrich). To induce RAS acti-
vation in ATIIER:KRASV12 cells, 250 nM 4-OHT (Sigma-
Aldrich) was added [17, 18]. MRC5 cells were obtained from
the European Collection of Authenticated Cell Cultures
(ECACC) and were cultured in DMEM (Thermo Fisher
Scientific). Both cell culture media were supplemented with
10% FBS (Thermo Fisher Scientific), 1% penicillin/strepto-
mycin and glutamine (Thermo Fisher Scientific). All cells
were kept at 37 °C and 5% CO2. For 3D culture, ATII
ER:
KRASV12 cells were cultured as previously described [23] in
Matrigel (BD Biosciences). TGFα was from Fisher Scientific
UK Ltd. TGFβ1 was from PeproTech. EGF and recombinant
human tPA protein were from Bio-Techne. AKT VIII and
U0126 were from Sigma Aldrich. No mycoplasma con-
tamination was detected in the cell lines used.
Short interfering RNA (siRNA) oligos against ZEB1
(MU-006564-02-0002), SNAI1 (Snail1) (MU-010847-00-
0002), SNAI2 (Snail2) (MU-017386-00-0002) and PLAT
(tPA) (MU-005999-01-0002) were purchased from Dhar-
macon. Sequences are available from Dharmacon, or on
request. As a negative control, we used siGENOME RISC-
Free siRNA (Dharmacon). ATIIER:KRASV12 cells were
transfected with the indicated siRNA oligos at a final con-
centration of 35 nM using DharmaFECT 2 reagent
(Dharmacon).
Western blot analysis
Western blot analysis was performed with lysates from cells
with urea buffer (8 M urea, 1 M thiourea, 0.5% CHAPS, 50
mM DTT and 24 mM Spermine). Primary antibodies were
from Santa Cruz (β-actin, sc-47778; ZEB1, sc-25388;
ZEB2, sc-48789; E-cadherin, sc-21791; Snail2, sc-10436),
Abcam (β-tubulin, ab6046), Cell Signalling Technology (α-
SMA, 14968; phospho-AKT, 9271; phospho-ERK, 9101;
Snail1, 3879; Snail2, 9585; TWIST, 46702; Phospho-
Smad2, 3104; β-tubulin, 86298), BD Transduction
Laboratories (E-cadherin, 610405; Vimentin, 550513) and
Millipore (proSP-C, AB3786; tPA, 05-883). Signals were
detected using an Odyssey imaging system (LI-COR), and
evaluated by ImageJ 1.42q software (National Institutes of
Health).
qRT-PCR
Total RNA was isolated using RNeasy mini kit (Qiagen)
according to manufacturer’s instructions and quantified using
a Nanodrop Spectrophotometer 2000c (Thermo Fisher Sci-
entific). Real-time quantitative RT-PCR was carried out
using gene-specific primers (QuantiTect Primer Assays,
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Qiagen) for CDH1 (E-cadherin) (QT00080143), SNAI1
(Snail1) (QT00010010), SNAI2 (Snail2) (QT00044128),
ZEB1 (QT00008555), ZEB2 (QT00008554), TWIST
(QT00011956), VIM (QT00095795), COL1A1
(QT00037793), COL3A1 (QT00058233), FN1
(QT00038024), ACTA2 (α-SMA) (QT00088102), PLAT
(tPA) (QT00075761), TGFB1 (QT00000728), TGFB2
(QT00025718), GAPDH (QT01192646) or ACTB (β-actin)
(QT01680476) with QuantiNova SYBR Green RT-PCR kits
(Qiagen). Relative transcript levels of target genes were
normalised to GAPDH or ACTB (β-actin).
Immunofluorescence microscopy
Cells were fixed in 4% PBS-paraformaldehyde for 15 min,
incubated in 0.1% Triton X-100 for 5 min on ice, then in
0.2% fish skin gelatin in PBS for 1 h and stained for 1 h
with an anti-Prosurfactant Protein C (proSP-C) antibody
(1:100, Millipore AB3786, rabbit polyclonal) or anti-ZEB1
(1:100, Santa Cruz sc-25388, rabbit polyclonal). Protein
expression was detected using Alexa Fluor (1:400, Mole-
cular Probes) for 20 min. DAPI (Invitrogen) was used to
stain nuclei (1:1000). Rhodamine-phalloidin was used to
visualise filamentous actin (F-actin) (Molecular Probes).
For immunofluorescence staining of 3D cultures from
ATIIER:KRASV12 cells, spheres were fixed with 4% PBS-
paraformaldehyde for 40 min, permeabilised in 0.5% Triton
X-100 for 10 min on ice and stained with rhodamine-
phalloidin for 1 h at room temperature. Spheres were
counterstained with DAPI. Samples were observed using a
confocal microscope system (Leica SP8). Acquired images
were analysed using Photoshop (Adobe Systems) according
to the guidelines of the journal.
Immunohistochemistry, haematoxylin and eosin (H/
E) and tinctorial stains
Control or IPF lung tissues (n= 3 donors) were fixed and
embedded in paraffin wax; tissue sections (4 µm) were
processed and stained as previously described [20]. Briefly,
the tissue sections were de-waxed, rehydrated and incubated
with 3% hydrogen peroxide in methanol for 10 min to block
endogenous peroxidase activity. Sections were then blocked
with normal goat serum and incubated at room temperature
with a primary antibody against ZEB1 (1:500, Sigma),
followed by a biotinylated secondary antibody (1:500,
Vector Laboratories Ltd., UK); antibody binding was
detected using streptavidin-conjugated horse-radish perox-
idase and visualised using DAB (DAKO) before counter-
staining with Mayer’s Haematoxylin. For H/E stain,
Shandon Varistain 24-4 automatic slide stainer (Thermo
Fisher Scientific) was used. For tinctorial stain, Trichrome
stain (Abcam ab150686) was used according to the
manufacturers’ instructions. Images were acquired using an
Olympus Dotslide Scanner VS110.
Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out using SimpleChIP enzymatic
chromatin IP kits (Cell Signalling Technology) as per the
manufacturer’s instructions. Briefly, ATIIER:KRASV12 cells
with indicated treatments were incubated for 10 min with
1% formaldehyde solution at room temperature, followed
by incubation with 125 mM glycine. Antibodies used for
ChIP were as follows: rabbit anti-ZEB1 (PA5-28221,
Invitrogen, rabbit polyclonal, 5 μg per IP sample), normal
rabbit IgG (2729, Cell Signalling Technology, 5 μg per IP
sample). For the ZEB1 binding site at position −419 of
the human PLAT (tPA) promoter, the primers amplifying
the region between −547 and −345 were as follows: for-
ward 5′-GGAAAGTCCCCGGAGGCCACCTA-3′ and
reverse 5′-TGGAACACTTTGTGTGGTGGC-3′. DNA
fragments were quantified by qPCR. PCR products were
analysed in a 1.5% agarose gel by ethidium bromide
staining.
Luciferase constructs and luciferase reporter assays
The human PLAT (tPA) promoter (sequence −689 to −1
upstream of the TSS) was amplified from human genomic
DNA by PCR, and was subsequently cloned into pGL3
basic vector (Promega), termed pGL3 basic-PLAT (−689 to
−1). The putative ZEB1 binding site, positioned −419 to
−414 on the human PLAT promoter, was removed from
pGL3 basic-PLAT (−689 to −1) construct to create the
pGL3 basic-Δ ZEB1 motif construct.
For the luciferase reporter assays, ATIIER:KRASV12 cells
were transfected using Lipofectamine 3000 (Invitrogen)
with 80 ng of phRL-CMV (Promega), which constitutively
expresses the Renilla luciferase reporter, plus 600 ng of
pGL3 basic-PLAT (−689 to −1) or pGL3 basic-Δ ZEB1
motif per well in the presence or absence of 4-OHT. Finally,
the transcriptional assay was carried out using the Dual-
Luciferase reporter assay system (Promega) following the
manufacturer’s protocol.
Quantitative proteomic analysis of the secretome
and the subsequent data analysis
Serum-free CM from ATIIER:KRASV12 cells treated without
or with 4-OHT (250 nM, 24 h) were analysed using an
enrichment strategy based upon Strataclean resin (Agilent)
in combination with the quantitative label-free approach,
LC-MSE, to provide in-depth proteome coverage and esti-
mates of protein concentration in absolute amounts [52]
(details provided in Supplementary Methods).
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Raw data were processed and collated into a single.csv
document. Values were then normalised to total fmol of
each sample multiplied by 10,000. Pseudo-counts were
applied to the normalised values to replace missing ones, to
allow for full statistical analysis to be completed [53]. We
first sorted the normalised values in each column in order of
abundance, in ascending order, then the minimum value of
each sample identified. This minimum was used to replace
all missing values in the data set. A two-tailed, unpaired
Student’s t-test was used to compare two groups for inde-
pendent samples. P < 0.05 was considered statistically
significant.
In order to highlight their implications in IPF, differen-
tially expressed proteins/genes identified in the quantitative
secretome analysis were searched in LGEA web portal
(https://research.cchmc.org/pbge/lunggens/mainportal.html)
for their levels in pulmonary epithelial cells from control
and IPF lung tissue.
Bioinformatics
IPF transcriptomic data was downloaded from the NCBI’s
Gene Expression Omnibus (GEO). We used data from
GSE24206 [15], a microarray study comparing samples
from 11 IPF patients undergoing lung transplantation or
diagnostic biopsy to six normal lung samples taken from
lung transplantation donors. Microarray series matrix files
were imported into R, and differential expression analysis
comparing normal to IPF samples performed using the R
package limma [54]. Data were log-transformed before
analysis. To correct for multiple testing, a
Benjamini–Hochberg FDR of 5% was applied to the data,
and a Q-value cut-off of 0.02 was used to determine sig-
nificance. Differentially expressed gene lists were input into
the human Consensus Pathways Database, which deter-
mined pathways with differentially expressed genes over-
represented in this database. A 5% FDR was used as above.
Statistical analysis and repeatability of experiments
Each experiment was repeated at least twice. Unless
otherwise noted, data are presented as mean and s.d., and a
two-tailed, unpaired Student’s t-test was used to compare
two groups for independent samples. P < 0.05 was con-
sidered statistically significant.
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